anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We previously reported that brain atrophy was more severe and progressed more rapidly in patients with end-stage kidney disease on peritoneal dialysis (PD) than those with non-dialysis-dependent chronic kidney disease. However, it remains unknown whether there is a difference between patients on PD and hemodialysis (HD). In total, 73 PD and 34 HD patients who underwent brain magnetic resonance imaging (MRI) were recruited for a cross-sectional analysis. Among them, 42 PD and 25 HD patients who underwent a second brain MRI after 2 years were recruited for a longitudinal analysis. T1-weighted MRI images were analyzed. Total gray matter volume (GMV), total white matter volume, and cerebrospinal fluid volume were segmented, and each volume was quantified using statistical parametric mapping software. The ratio of GMV (GMR) was calculated by dividing GMV by intracranial volume, to adjust for variations in head size. We compared GMR between PD and HD patients in the cross-sectional analysis and the annual change in GMR (AC-GMR) in the longitudinal analysis. In the cross-sectional analysis, age- and sex-adjusted GMR was significantly lower in PD than HD patients [least square mean (LSM): 39.2% vs. 40.0%, P = 0.018]. AC-GMR was significantly greater in PD than HD patients and this difference remained significant even after adjustment for potential confounding factors (LSM: -0.68 vs. -0.28 percentage-points/year, P = 0.011). In conclusion, the present study demonstrated a more rapid progression of brain atrophy in PD patients compared with HD patients. We demonstrated that decline in GMR progressed significantly more rapidly in PD than HD patients independent of potential confounding factors. GMR gray matter volume ratio, HD hemodialysis, PD peritoneal dialysis.
FIELD: medicine, dermatology. SUBSTANCE: method involves simultaneous isolation of all virus localization sites both into organism and on its surfaces including cavities covered with mucous membranes by oral administration and application of antiviral solution on the body damaged sites. Antiviral solution has trinitrotoluene, dimethylsulfoxide, boric and/or benzoic, and/or salicylic acid, glycerol and ethyl alcohol in complex with antibacterial solution and ointments containing trinitrotoluene, vegetable oil, benzoic acid, lubricant grease and pig fat. External therapy is carried out for 6-10 h, once per a day and every other day, and internal therapy - every day, at least twice per a day, by 1-10 ml. EFFECT: prolonged remission period, total recovery of tissues and organs, enhancement of protective properties of organism. 5 cl
A packaged gas-solubilized product is described. The gas-solubilized product contains a first gas with a first pressure. The product is placed into a flexible inner container (2) made of a gas-impermeable material. The inner container is hermetically disposed inside an outer container (1). A space (4) formed between the inner and the outer containers is charged with a second gas with an initial charging pressure. The initial charging pressure is higher than the pressure of the first gas contained in the product. Additionally, a product dispenser (3) in a fluid connection with the product contained in the internal container is included. The present invention also provides a method of packaging a gas-solubilized product to prevent a change in the concentration of the gas dissolved in the product during its storage and dispensing.
Operations performed for liver hemangioma at Ankara University Hospitals will be retrospectively analyzed. Patient and disease characteristics including demographics, laboratory tests, imaging studies, type of surgical approach and outcomes including postoperative laboratory tests, record of complications, duration of hospital stay will be reviewed. Complications were classified according to Clavien-Dindo classification. The patients were informed about the surgeries in advance and their informed consents about surgeries and data collection for scientific purposes were obtained. Datafile will be anonymized before analysis and original file will be destroyed. Outcomes such as complications, hospital stay, blood transfusion and mortality will be compared between groups created according to type of surgery, lesion size, preoperative laboratory values and demographic features. Variables for prediction of better outcomes are expected to be discovered.
Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Check for minute leaks by squeezing bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below. Check solution for clarity and absence of foreign matter. If solution is not clear or contains foreign matter, discard the solution.
Sepsis following burn trauma is a global complication with high mortality, with ∼60% of burn patient deaths resulting from infectious complications. Diagnosing sepsis is complicated by confounding clinical manifestations of the burn injury, and current biomarkers lack the sensitivity and specificity required for prompt treatment. There is a strong rationale to assess circulating extracellular vesicles (EVs) from patient liquid biopsy as sepsis biomarkers due to their release by pathogens from bacterial biofilms and roles in the subsequent immune response. This study applies Raman spectroscopy to patient plasma-derived EVs for rapid, sensitive, and specific detection of sepsis in burn patients, achieving 97.5% sensitivity and 90.0% specificity. Furthermore, spectral differences between septic and non-septic burn patient EVs could be traced to specific glycoconjugates of bacterial strains associated with sepsis morbidity. This work illustrates the potential application of EVs as biomarkers in clinical burn trauma care and establishes Raman analysis as a fast, label-free method to specifically identify features of bacterial EVs relevant to infection amongst the host background.
Several factors may contribute to binge eating behaviors in PCOS. However, findings are contradictory and studies in the adolescence are limited. We aimed to evaluate the eating attitudes of adolescents with PCOS and the possible etiological factors underlying the association between PCOS and binge eating symptomology. Between 2019 and 2022, 46 newly diagnosed adolescents with PCOS and 56 controls matched for age and BMI z-score were included. The Eating Disorder Examination Questionnaire, Three Factor Eating Questionnaire-R18, and a questionnaire assessing postprandial reactive hypoglycemia symptom severity were given. Binge eating symptomology, in terms of over, uncontrolled, and emotional eating, were more prevalent in the PCOS group. Uncontrolled, emotional, and binge eating were positively correlated with postprandial reactive hypoglycemia symptom score. Overeating was also associated with clinical hyperandrogenism. Improving the disease outcome and reducing the future complications requires early recognition and management of emotional and uncontrolled eating behaviors in adolescents with PCOS.
A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2.
The present invention relates to light insensitive and thermally stable antimicrobial formulations of electrolytically generated transition metal ions. The specific combination of metal ions gives it a broad spectrum anti-microbial ability against potentially pathogenic bacteria, virus, fungi, mold, mildew and antibiotic resistant species. The low viscosity formulations of the present invention are easy to be dosed, stand alone preservatives, providing a big change in the cosmetics and food industry. These eco-friendly formulations are effective alternatives to formaldehyde donors and parabens, with high bioavailability in water and oily phases. The alcohol and surfactants free formulations are effective in very small doses. Since, no organometallics or salts are used as the metal source in the present invention, this makes the formulations safe for sensitive applications such as in the cosmetics and food industry.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Controlled clinical trials: The most frequent adverse reactions associated with dorzolamide hydrochloride ophthalmic solution were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. Superficial punctate keratitis occurred in 10 to 15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%. Reactions occurring in approximately 1 to 5% of patients were conjunctivitis and lid reactions [ see Warnings and Precautions (5.4)], blurred vision, eye redness, tearing, dryness, and photophobia. Other ocular reactions and systemic reactions were reported infrequently, including headache, nausea, asthenia/fatigue; and, rarely, skin rashes, urolithiasis, and iridocyclitis. 

In a 3-month, double-masked, active-treatment-controlled, multicenter study in pediatric patients, the adverse reactions profile of dorzolamide hydrochloride ophthalmic solution was comparable to that seen in adult patients.
Cases of cervical precancer will include women diagnosed with cervical intraepithelial grades 2 or 3 (CIN2/3) or adenocarcinoma in situ (AIS). If any women are diagnosed with cancer in the study, they will be included in this group.
The control cohort will consist of a group of people from the same age group as the CKD group but without chronic kidney disease. The exclusion criteria apply to this group. They will be selected from the spouses and other volunteers. This group will also perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
The present invention relates to a Chinese patent medicine resisting coronary heart disease, which is prepared by using notoginseng and epimedium herb as raw materials and belongs to the technical field of medicine preparation. The present invention comprises the following formulation: the weight ratio of total arasaponin to total flavonoid of epimedium herb is from 0.2 to 5. The present invention has the advantages of filling the gap that no second-category new medicine for curing coronary heart disease, angina pectoris and diseases exists. The compound second category new Chinese medicine also has the effect of activating blood circulation to dissipate blood stasis and warming yang to eliminate numbness medicinal effect experiments and small scale clinical tests. Pharmacodynamics experiments verify that the medicine has an obvious protective function for acute myocardial ischemia caused by pituitrin, can also obviously enhance the coronary blood flow of dopey dogs, lower the resistance of the coronary artery and the total peripheral resistance, and reduce the oxygen consuming content of the cardiac muscle, the degree of myocardial ischemia, the range of myocardial ischemia and the area of myocardial infarction. Toxicity experiments indicate that the medicine has tiny toxicity. When together used, both medicines of the prescription not only have obviously enhanced medicinal effect compared with the condition that either medicine is singly used, but also has the function of reducing toxicity.
The present invention relates to the delivery of rizatriptan or zolmitriptan through an inhalation route. Specifically, it relates to aerosols containing rizatriptan or zolmitriptan that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of rizatriptan or zolmitriptan. In a method aspect of the present invention, either rizatriptan or zolmitriptan is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of rizatriptan or zolmitriptan, to form a vapor; and b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of rizatriptan or zolmitriptan; and, b) a device that forms a rizatriptan or zolmitriptan containing aerosol from the composition, for inhalation by the mammal.
OBJECTIVE: Most bladder cancers are nonmuscle invasive bladder cancer (NMIBC), and transurethral resection of bladder tumors (TURBT) is the standard treatment. However, postoperative recurrence remains a significant challenge, and the influence of bladder tumor location on prognosis is still unclear. This study aims to investigate how tumor location affects the prognosis of NMIBC patients undergoing TURBT and to identify the optimal surgical approach.
METHODS: A multicenter study was conducted, which included Chinese NMIBC data from 15 hospitals (1996-2019) and data from 17 registries of the Surveillance, Epidemiology, and End Results database (SEER) (2000-2020). Patients initially diagnosed with NMIBC and undergoing TURBT or partial cystectomy were analyzed, with cases lost to follow-up or with missing data excluded. The study investigated the overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) among patients with different tumor locations. Kaplan-Meier, Cox regression, and propensity score matching methods were employed to explore the association between tumor location and prognosis. Stratified populations were analyzed to minimize bias.
RESULTS: This study included 118 477 NMIBC patients and highlighted tumor location as a crucial factor impacting post-TURBT prognosis. Both anterior wall and dome tumors independently predicted adverse outcomes in two cohorts. For anterior wall tumors, the Chinese cohort showed hazard ratios (HR) for OS of 4.35 ( P <0.0001); RFS of 2.21 ( P <0.0001); SEER cohort OS HR of 1.10 ( P =0.0001); DSS HR of 1.13 ( P =0.0183). Dome tumors displayed similar trends [Chinese NMIBC cohort OS HR of 7.91 ( P <0.0001); RFS HR of 2.12 ( P <0.0001); SEER OS HR of 1.05 ( P =0.0087); DSS HR of 1.14 ( P =0.0006)]. Partial cystectomy significantly improved the survival of dome tumor patients compared to standard TURBT treatment ( P <0.01).
CONCLUSION: This study reveals the significant impact of tumor location in NMIBC patients on the outcomes of TURBT treatment, with tumors in the anterior wall and bladder dome showing poor post-TURBT prognosis. Compared to TURBT treatment, partial cystectomy improves the prognosis for bladder dome tumors. This study provides guidance for personalized treatment and prognosis management for NMIBC patients.
Long-term unemployment has a profound impact on the health and wellbeing of individuals, families, and communities. In addition, the effects of long-term unemployment have been found to impact subgroups differently. Today there is scant knowledge on the mechanisms that are influential in moving individuals from long-term unemployment closer to the labor market. This study is designed to answer six research questions using a variety of methods (mixed-methods) and outcome measures (self-report, official register). In addition, this study leverages official register data to construct an untreated control group. This study will assess the extent to which an emerging theory of becoming job ready holds under experimental scrutiny.

This project will engage ALMP program administrators and service providers in semi-structured interviews. A total of 6 competing ALMPs will be included in the study. The transcribed interview material will be used as a basis for program theory reconstruction. All specified program theories will be presented back to program stakeholders for validation. ALMP program effectiveness will be assessed quasi-experimentally with pre- (T1) and posttest (T2) collection of self-reported data. Additionally, official register data from the Longitudinal integrated database for health insurance and labor market studies (LISA) will be collected for all participants. In addition, a matched sample will be collected from LISA to be used as a non-treated control group on final policy outcomes (e.g., employment, salary/wage). This study also assesses program implementation and economic outcomes of competing the competing ALMPs.
PROBLEM TO BE SOLVED: To obtain a reactive tricalcium phosphate composition stable at room temperatures and giving α-tricalcium phosphate products in a pure phase by including a physiologically acceptable lubricant and a calcium phosphate cement composition comprising reactive α-tricalcium phosphate, a calcium source and a partially neutralized phosphoric acid source. SOLUTION: Reactive α-tricalcium phosphate is produced by reacting a stoichiometric mixture of CaHPO4 and CaCO3 with each other in an aqueous reaction solvent at a pressure of 0.35-2.1 kg/cm<2> , heating the obtained product having a Ca : phosphate group ratio of 1.5:1 at 1200-1700 deg.C for 1-8 hr and subsequently quenching the product. >=20 wt.% of the obtained reactive α-tricalcium phosphate is compounded with 0.1-10 wt.% of at least one kind of an additional calcium source (e.g. calcium hydroxide) and 1.0-40 wt.% of a partially neutralized phosphoric acid source to obtain a calcium phosphate cement composition. The composition is compounded with a physiologically acceptable lubricant (e.g. water) to provide the objective reactive tricalcium phosphate composition.
Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least tow first line anti-tuberculous drugs such as INH and rifampicin. Frequently, such MDR strains show resistance to all commonly used first-line agents i.e INH, rifampicin, streptomycin, ethambutol and pyrazinamide. Isoniazid is the most widely used anti-tuberculous drug. Resistance to isoniazid can occur by increased expression on inhA or by mutations that lower the enzyme's affinity to NADH. Mutations in katG, which encodes catalase peroxidase, is the most common source of resistance. Another mechanism of isoniazid resistance occurs by defects in NADH dehydrogenase (Ndh) of the respiratory chain. Increases expression of AhpC has been suggested as another mechanism of INH resistance in mycobacteria. The present invention provides method of treating drug resistance for Mycobacterium tuberculosis infection. According to present invention, a method is provided to employ penicillin with INH. This reduces the MIC of INH and makes resistant organisms sensitive. The level of penicillins required for reversal of INH resistance is known to be achieved and maintained by therapeutic doses of penicillins.
Patients receive BO-112 intratumorally on days 8 and 15 or 1, 8, and 15 and nivolumab IV over 30-60 minutes on day 8 in the absence of disease progression or unacceptable toxicity. Patients also undergo standard of care radiation therapy on days 8-12 for a total of 5 fractions. Patients then undergo standard of care definitive surgical resection on day 26 to 50.
Amplibody compositions and methods used to interact with agglomeration proteins and initiate and mediate an aggregation cascade are disclosed herein. Compositions herein comprise one or more DNA or RNA molecules having affinity for at least one agglomeration protein. The nucleic acid component is a naturally occurring or non-naturally occurring molecule with twenty or more ribonucleotide bases. For RNA, at least one nucleotide sequence portion of this RNA molecule has affinity to at least one consensus sequence present in the agglomeration RNA-binding protein. The isolated RNA molecules of the present invention bind agglomeration proteins to initiate and mediate the progression of a nucleo-protein aggregation cascade. The nucleo-protein aggregation cascade can be self-catalyzing, with formation of intermediate aggregates comprising an RNA molecule and one or more agglomeration proteins.
Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) belonging to the chemical series, the 2-aminoethyl oxime ethers of aralkylketones.

It is chemically unrelated to other SSRIs and clomipramine. It is chemically designated as 5-methoxy-4′-(trifluoromethyl)valerophenone-(E)-O-(2-aminoethyl) oxime maleate (1:1) and has the molecular formula C15H21O2N2F3∙C4H4O4. Its molecular weight is 434.41.

The structural formula is:

Fluvoxamine maleate, USP is a white to off-white, odorless, crystalline powder which is sparingly soluble in water, freely soluble in ethanol and chloroform and practically insoluble in diethyl ether.

Fluvoxamine maleate tablets, USP are available in 25 mg, 50 mg and 100 mg strengths for oral administration. In addition to the active ingredient, fluvoxamine maleate, USP, each tablet contains the following inactive ingredients: carnauba wax, corn starch, magnesium stearate, mannitol, methylcellulose, pregelatinized starch (corn) and sodium starch glycolate (potato). The tablet coating contains hypromellose, polyethylene glycol, polysorbate 80, titanium dioxide and yellow iron oxide. The 100 mg tablets also contain red iron oxide.
Three-dimensional (3D) ultrasound can assess the margins of resected tongue carcinoma during surgery. Manual segmentation (MS) is time-consuming, labour-intensive, and subject to operator variability. This study aims to investigate use of a 3D deep learning model for fast intraoperative segmentation of tongue carcinoma in 3D ultrasound volumes. Additionally, it investigates the clinical effect of automatic segmentation. A 3D No New U-Net (nnUNet) was trained on 113 manually annotated ultrasound volumes of resected tongue carcinoma. The model was implemented on a mobile workstation and clinically validated on 16 prospectively included tongue carcinoma patients. Different prediction settings were investigated. Automatic segmentations with multiple islands were adjusted by selecting the best-representing island. The final margin status (FMS) based on automatic, semi-automatic, and manual segmentation was computed and compared with the histopathological margin. The standard 3D nnUNet resulted in the best-performing automatic segmentation with a mean (SD) Dice volumetric score of 0.65 (0.30), Dice surface score of 0.73 (0.26), average surface distance of 0.44 (0.61) mm, Hausdorff distance of 6.65 (8.84) mm, and prediction time of 8 seconds. FMS based on automatic segmentation had a low correlation with histopathology (r = 0.12, p = 0.67); MS resulted in a moderate but insignificant correlation with histopathology (r = 0.4, p = 0.12, n = 16). Implementing the 3D nnUNet yielded fast, automatic segmentation of tongue carcinoma in 3D ultrasound volumes. Correlation between FMS and histopathology obtained from these segmentations was lower than the moderate correlation between MS and histopathology.